Critical Drug-Drug Interactions for Use in Electronic Health Records Systems With Computerized Physician Order Entry: Review of Leading Approaches

被引:44
作者
Classen, David C. [1 ,2 ]
Phansalkar, Shobha [3 ,4 ,5 ]
Bates, David W. [3 ,4 ,5 ]
机构
[1] Univ Utah, Sch Med, Div Infect Dis, Salt Lake City, UT USA
[2] CSC, Salt Lake City, UT USA
[3] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Partners HealthCare Syst, Wellesley, MA USA
关键词
drug-drug interactions; clinical decision support; electronic health records; patient safety;
D O I
10.1097/PTS.0b013e31821d6f6e
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Medications represent the most common intervention in health care, despite their benefits; they also lead to an estimated 1.5 million adverse drug events and tens of thousands of hospital admissions each year. Although some are not preventable given what is known today, many types are, and one key cause which is preventable is drug-drug interactions (DDIs). Most electronic health record systems include programs that can check and prevent these types of interactions as a routine part of medication ordering. Studies suggest that these systems as implemented often do not effectively screen for these DDIs. A major reason for this deficiency is the lack of any national standard for the critical DDIs that should be routinely operationlized in these complex systems. We review the leading critical DDI lists from multiple sources including several leading health systems, a leading commercial content provider, the Leapfrog CPOE Testing Standard, and the new Office of the National Coordinator (ONC) DDI List. Implementation of strong DDI checking is one of the important steps in terms of realizing the benefits of electronic prescribing with respect to safety. Hopefully, the ONC list will make it easier for organizations to ensure they are including the most important interactions, and the Leapfrog List may help these organizations develop an operational DDI list that can be practically implemented. In addition, this review has identified 7 common DDIs that can be the starting point for all organizations in this area of medication safety.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 40 条
  • [1] Core Drug-Drug Interaction Alerts for Inclusion in Pediatric Electronic Health Records With Computerized Prescriber Order Entry
    Harper, Marvin B.
    Longhurst, Christopher A.
    McGuire, Troy L.
    Tarrago, Rod
    Desai, Bimal R.
    Patterson, Al
    JOURNAL OF PATIENT SAFETY, 2014, 10 (01) : 59 - 63
  • [2] Using Linked Data for Mining Drug-Drug Interactions in Electronic Health Records
    Pathak, Jyotishman
    Kiefer, Richard C.
    Chute, Christopher G.
    MEDINFO 2013: PROCEEDINGS OF THE 14TH WORLD CONGRESS ON MEDICAL AND HEALTH INFORMATICS, PTS 1 AND 2, 2013, 192 : 682 - 686
  • [3] Structured override reasons for drug-drug interaction alerts in electronic health records
    Wright, Adam
    McEvoy, Dustin S.
    Aaron, Skye
    McCoy, Allison B.
    Amato, Mary G.
    Kim, Hyun
    Ai, Angela
    Cimino, James J.
    Desai, Bimal R.
    El-Kareh, Robert
    Galanter, William
    Longhurst, Christopher A.
    Malhotra, Sameer
    Radecki, Ryan P.
    Samal, Lipika
    Schreiber, Richard
    Shelov, Eric
    Sirajuddin, Anwar Mohammad
    Sittig, Dean F.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2019, 26 (10) : 934 - 942
  • [4] Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records
    Phansalkar, Shobha
    van der Sijs, Heleen
    Tucker, Alisha D.
    Desai, Amrita A.
    Bell, Douglas S.
    Teich, Jonathan M.
    Middleton, Blackford
    Bates-, David W.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2013, 20 (03) : 489 - 493
  • [5] Functionality test for drug safety alerting in computerized physician order entry systems
    van der Sijs, Heleen
    Bouamar, Rachida
    van Gelder, Teun
    Aarts, Jos
    Berg, Marc
    Vulto, Arnold
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2010, 79 (04) : 243 - 251
  • [6] Variation in high-priority drug-drug interaction alerts across institutions and electronic health records
    McEvoy, Dustin S.
    Sittig, Dean F.
    Hickman, Thu-Trang
    Aaron, Skye
    Ai, Angela
    Amato, Mary
    Bauer, David W.
    Fraser, Gregory M.
    Harper, Jeremy
    Kennemer, Angela
    Krall, Michael A.
    Lehmann, Christoph U.
    Malhotra, Sameer
    Murphy, Daniel R.
    O'Kelley, Brandi
    Samal, Lipika
    Schreiber, Richard
    Singh, Hardeep
    Thomas, Eric J.
    Vartian, Carl V.
    Westmorland, Jennifer
    Mccoy, Allison B.
    Wright, Adam
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2017, 24 (02) : 331 - 338
  • [7] Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records
    Phansalkar, Shobha
    Desai, Amrita
    Choksi, Anish
    Yoshida, Eileen
    Doole, John
    Czochanski, Melissa
    Tucker, Alisha D.
    Middleton, Blackford
    Bell, Douglas
    Bates, David W.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2013, 13
  • [8] Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records
    Shobha Phansalkar
    Amrita Desai
    Anish Choksi
    Eileen Yoshida
    John Doole
    Melissa Czochanski
    Alisha D Tucker
    Blackford Middleton
    Douglas Bell
    David W Bates
    BMC Medical Informatics and Decision Making, 13
  • [9] A Review of Approaches for Predicting Drug-Drug Interactions Based on Machine Learning
    Han, Ke
    Cao, Peigang
    Wang, Yu
    Xie, Fang
    Ma, Jiaqi
    Yu, Mengyao
    Wang, Jianchun
    Xu, Yaoqun
    Zhang, Yu
    Wan, Jie
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [10] A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems
    Qian, Yifeng
    Ye, Xiaofei
    Du, Wenmin
    Ren, Jingtian
    Sun, Yalin
    Wang, Hainan
    Luo, Baozhang
    Gao, Qingbin
    Wu, Meijing
    He, Jia
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (01) : 67 - 73